These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 25558073)
1. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073 [TBL] [Abstract][Full Text] [Related]
2. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618 [TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study. Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536 [TBL] [Abstract][Full Text] [Related]
4. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis. Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277 [TBL] [Abstract][Full Text] [Related]
6. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Li X; Yu C; Wang T; Chen K; Zhai S; Tang H Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292 [TBL] [Abstract][Full Text] [Related]
11. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis? Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913 [TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338 [TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes. Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH Platelets; 2015; 26(2):148-53. PubMed ID: 24617511 [TBL] [Abstract][Full Text] [Related]
19. Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Trubiano JA; Paratz E; Wolf M; Teh BW; Todaro M; Thursky KA; Slavin MA Mycoses; 2014 Sep; 57(9):572-6. PubMed ID: 24761988 [TBL] [Abstract][Full Text] [Related]
20. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. Abidi MZ; D'Souza A; Kuppalli K; Ledeboer N; Hari P Diagn Microbiol Infect Dis; 2015 Sep; 83(1):46-8. PubMed ID: 25986028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]